Travere Therapeutics, Inc.
https://travere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Travere Therapeutics, Inc.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
AstraZeneca’s Danicopan Among Four Orphans Up For EU Approval Decision
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.
Asia Deal Watch: Takeda To Team Up With Protagonist On Treatment For Polycythemia Vera
Plus alliances involving Formosa/Cristalia, Renalys/Travere, Astellas/Vivtex, Zydus/Synthon, AFT/Hyloris and Astellas/Mass General Brigham hospital.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Desert Gateway, Inc.
- Kyalin Biosciences, Inc.
- Manchester Pharmaceuticals LLC.
- Orphan Technologies Ltd.
- Retrophin, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice